Dronedarone vs. placebo in patients with atrial fibrillation or atrial flutter across a range of renal function: a<i>post hoc</i>analysis of the ATHENA trial — Máté Vámos (2021) | RDL Network
Dronedarone vs. placebo in patients with atrial fibrillation or atrial flutter across a range of renal function: a<i>post hoc</i>analysis of the ATHENA trial
Article 2021 en
Authors
MV
Máté Vámos
JO
Jonas Oldgren
GN
Gi‐Byoung Nam
Abstract
1 min read
Dronedarone is an effective AAD in patients with AF/AFL and CV risk factors across a wide range of renal function.
Giuseppe Boriani, Marco Proietti, C Laroche, Igor Diemberger, Zbigniew Kalarus, Tatjana Potpara, Laurent Fauchier, Harry J.G.M. Crijns, Aldo P. Maggioni, Professor Gregory Lip
Yang Liu, Steven Ho Man Lam, Giulio Francesco Romiti, Bi Huang, Yang Chen, Tze-Fan Chao, Brian Olshansky, Kui Hong, Menno V. Huisman, Professor Gregory Lip
Discussion(0)
No comments yet. Be the first to comment.